NCT05367063View on ClinicalTrials.gov

Canagliflozin and Myocardial Fibrosis

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

March 20, 2025

Conditions
Type 2 DiabetesCardiovascular DiseasesCardiac Perfusion Defect
Interventions
DRUG

Canagliflozin 100mg or Sitagliptin 100mg

Eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.

Trial Locations (1)

200000

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT05367063 - Canagliflozin and Myocardial Fibrosis | Biotech Hunter | Biotech Hunter